Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018:175:127-137.
doi: 10.1007/978-3-319-93339-9_6.

Advances in the Treatment of Metastatic Renal Cell Carcinoma

Paulo Bergerot  1 , Kathy Burns  1 , Dhruv Prajapati  1 , Rachel Fox  1 , Meghan Salgia  1 , Sumanta K Pal  2
Affiliations

Advances in the Treatment of Metastatic Renal Cell Carcinoma

Paulo Bergerot et al. Cancer Treat Res. 2018.

Abstract

The treatment landscape for metastatic renal cell carcinoma has constantly been in flux. In 2005, with the advent of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) therapy, the standard of care shifted to agents such as sunitinib and pazopanib. However, more recently there have been datasets, suggesting that next-generation TKIs such as cabozantinib may play an important role in therapy. Furthermore, immunotherapy has had resurgence with the FDA approval of nivolumab with ipilimumab. In the current chapter, we attempt to contextualize available frontline therapies for metastatic renal cell carcinoma with a focus on the CABOSUN and CheckMate 214 clinical trials.

Keywords: CABOSUN; CheckMate 214; Metastatic.

PubMed Disclaimer

MeSH terms

Substances

LinkOut - more resources